Found: 5
Select item for more details and to access through your institution.
Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT).
- Published in:
- Clinical Infectious Diseases, 2024, v. 78, n. 6, p. 1473, doi. 10.1093/cid/ciae043
- By:
- Publication type:
- Article
Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
- Published in:
- 2017
- By:
- Publication type:
- journal article
New Antimicrobial Agents . . . but No Susceptibility Tests!
- Published in:
- 2016
- By:
- Publication type:
- Letter to the Editor
Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2015, v. 70, n. 9, p. 2488, doi. 10.1093/jac/dkv131
- By:
- Publication type:
- Article
Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC).
- Published in:
- 2002
- By:
- Publication type:
- journal article